International Journal of Tropical Medicine
ISSN: Online 1818-779XISSN: Print 1816-3319
Abstract
Type 2 Diabetes Mellitus (T2DM) is a significant global health challenge, marked by insulin resistance and impaired insulin secretion. Effective management is crucial to preventing long‐term complications. Thiazolidinediones, including pioglitazone and lobeglitazone, are peroxisome proliferator‐activated receptor gamma (PPARγ) agonists used to improve insulin sensitivity. While pioglitazone is well‐established, lobeglitazone offers potential advantages with fewer adverse effects. This study aims to compare the efficacy and safety of these two drugs in managing T2DM. To compare the efficacy and safety of lobeglitazone versus pioglitazone in patients with Type 2 Diabetes Mellitus. This randomized controlled trial was conducted at a tertiary care hospital with a sample size of 140 patients, equally divided between the two drug groups (lobeglitazone and pioglitazone). Patients were assessed for glycemic control (HbA1c, fasting blood glucose), safety profiles, lipid profiles and cardiovascular risk markers over a 12‐month period. Statistical analysis was conducted using SPSS software, with p<0.05 considered significant. The study revealed that 64.3% of patients treated with lobeglitazone achieved an HbA1c target of <7%, compared to 50% in the pioglitazone group (p=0.04). Fasting blood glucose reduction was significantly greater in the lobeglitazone group (71.4% vs. 57.1%, p=0.03). Adverse events, including weight gain and edema, were less frequent in the lobeglitazone group (14.3% vs. 28.6%, p=0.02). Additionally, lobeglitazone had a more favorable impact on lipid profiles and cardiovascular risk markers, including triglyceride and HDL levels. Lobeglitazone demonstrated superior glycemic control and a better safety profile compared to pioglitazone, with fewer adverse events and more favorable effects on lipid profiles and cardiovascular risk markers. These findings suggest that lobeglitazone may be a safer and more effective alternative for managing T2DM, though long‐term studies are necessary to confirm its benefits.
How to cite this article:
Buddhiraj Patil. Comparative Study of Efficacy of Lobeglitazone Versus Pioglitazone in the Management of Type 2 Diabetes Mellitus.
DOI: https://doi.org/10.36478/10.36478/makijtm.2024.4.65.70
URL: https://www.makhillpublications.co/view-article/1816-3319/10.36478/makijtm.2024.4.65.70